0001104659-24-022566.txt : 20240213
0001104659-24-022566.hdr.sgml : 20240213
20240213214258
ACCESSION NUMBER: 0001104659-24-022566
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240209
FILED AS OF DATE: 20240213
DATE AS OF CHANGE: 20240213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sparks Charisse Y
CENTRAL INDEX KEY: 0001940873
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38468
FILM NUMBER: 24631638
MAIL ADDRESS:
STREET 1: C/O INSPIRE MEDICAL SYSTEMS, INC.
STREET 2: 9700 63RD AVENUE NORTH, SUITE 200
CITY: MAPLE GROVE
STATE: MN
ZIP: 55369
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inspire Medical Systems, Inc.
CENTRAL INDEX KEY: 0001609550
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 261377674
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 WAYZATA BLVD
STREET 2: SUITE 1600
CITY: GOLDEN VALLEY
STATE: MN
ZIP: 55416
BUSINESS PHONE: 763-957-5037
MAIL ADDRESS:
STREET 1: 5500 WAYZATA BLVD
STREET 2: SUITE 1600
CITY: GOLDEN VALLEY
STATE: MN
ZIP: 55416
4
1
tm245999-5_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-02-09
0
0001609550
Inspire Medical Systems, Inc.
INSP
0001940873
Sparks Charisse Y
C/O INSPIRE MEDICAL SYSTEMS, INC.
5500 WAYZATA BLVD., SUITE 1600
GOLDEN VALLEY
MN
55416
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-02-09
4
A
0
2694
0.00
A
3692
D
Employee Stock Option (Right to Buy)
194.87
2024-02-09
4
A
0
4376
0.00
A
2034-02-09
Common Stock
4376
4376
D
Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 9, 2025. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
The option vests and becomes exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
/s/ Bryan Phillips, Attorney-in-Fact for Charisse Y. Sparks, M.D.
2024-02-13